Best in Biotech 12 Jun 2023 Six advancements in Alzheimer’s research over the past year …compromised because of inflammatory mediators, cytokines, microglia, and it prevents these neuronal signals from firing,” said Berman who believes that COYA 301 has great therapeutic potential. In an eight-patient study… June 12, 2023 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jun 2022 ImCheck raises €96M in funding round …inhibitors. This method of cancer immunotherapy is made up of antibodies that block a so-called checkpoint protein that prevents immune cells from recognizing tumors. The company said that while it… June 17, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jul 2022 Drug for acute treatment of social anxiety disorder did not meet primary endpoint …and consistent with previously reported results from all other clinical trials. No severe or serious adverse events were reported for PH94B in prior clinical trials or in PALISADE-1. Nervous system… July 25, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2016 The First Peanut Allergy Therapy might soon hit the Shelves …layer without reaching the blood. Figure 1. Viaskin patch Since it does not reach the blood, the technology prevents anaphylactic reactions while still being able to present the antigen to… October 25, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Mar 2025 Cancer vaccines: 11 biotechs to keep an eye out for …patients, nine completed the full study and were relapse-free at the 12-month end of study visit. One patient discontinued the trial due to non-EVX-02-related adverse events (AEs) and was relapse-free… March 18, 2025 - 14 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 16 Nov 2022 Mineralys has positive topline results from trial evaluating treatment of hypertension …a safe and well-tolerated profile. The data from the Target-HTN trial demonstrated no notable effects on serum cortisol, supporting the selectivity of MLS-101 for aldosterone synthesis. Treatment-emergent, serious adverse events… November 16, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Development of cancer therapeutics accelerated by end-to-end single-cell multi-omics services …for a rich characterization of tumor evolution and heterogeneity. This must be done at a much higher resolution compared to bulk next-generation sequencing. This enables detection of rare events, at… July 13, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 14 Nov 2022 In depth interview: AstraZeneca/Sanofi RSV drug Beyfortus …particular mechanical ventilation, prevents fatal outcomes in virtually all infants. Prior to Beyfortus, palivizumab (another human monoclonal antibody) was approved to prevent RSV. It has been approved for high risk… November 14, 2022 - 9 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2017 This Herpes Cure is Proving to Work Better than its Predecessors …of new viral DNA copies, pritelivir prevents the whole process by inhibiting the helicase-primase complex that ‘opens’ the original DNA chain in order to be copied. In addition, it does… January 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 22 Feb 2018 GW Pharma’s Latest Cannabinoid Drug Pegged Back by a Placebo in Phase II …while the drug caused adverse events in an extra 25% of patients in comparison with the placebo arm. However, GW will not give up on the candidate just yet as… February 22, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 27 Apr 2017 Spain: An Emerging Star in the European Biotech Community …boasts more than 15 years’ tradition in drug discovery and preclinical research. For more than 10 years, BioCat, the biotech catalyst for Catalonia, organizes events at all levels connecting the… April 27, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2016 “We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease” …seen off-target effects or major severe adverse events in any of over 20 pediatric patients who comprise our rare disease pediatric clinical trials. So we are quite comfortable with HepaStem,… November 21, 2016 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email